Skip to main content

Table 2 Associations between HLE-E expression and histopathological parameters

From: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival

  

HLA-E low

HLA-E high

P value

  

n (%)

n (%)

 

Histology

SCC

42 (53)

37 (47)

0.010

(n = 192)

ASC

20 (53)

18 (47)

 
 

AC

23 (31)

52 (69)

 

Tumour stage

FIGO I

72 (44)

93 (56)

0.662

(n = 192)

FIGO II

13 (48)

14 (52)

 

HPV

Negative

7 (44)

9 (56)

0.965

(n = 192)

Positive

78 (44)

98 (56)

 

HPV type specific

HPV 16

42 (43)

56 (57)

0.949

(n = 151)

HPV 18

23 (43)

30 (57)

 

Tumour size

<40 mm

56 (45)

69 (55)

0.997

(n = 183)

> = 40 mm

26 (45)

32 (55)

 

Infiltration depth

<15 mm

47 (40)

70 (60)

0.112

(n = 186)

> = 15 mm

36 (52)

33 (48)

 

LVSI

Negative

32 (38)

53 (62)

0.045

(n = 174)

Positive

47 (53)

42 (47)

 

Resection margins

Tumour free

62 (42)

86 (58)

0.178

(n = 191)

Tumour positive

23 (54)

20 (47)

 

Parametria involvement

Tumour free

76 (43)

100 (57)

0.314

(n = 192)

Infiltrated

9 (56)

7 (44)

 

Lymph nodes

Negative

60 (43)

81 (57)

0.426

(n = 192)

Positive

25 (49)

26 (51)

 

Adjuvant radiotherapy

No

37 (39)

59 (61)

0.110

(n = 192)

Yes

48 (50)

48 (50)

 
  1. Human leukocyte antigen E (HLA-E) expression scores are dichotomized by the median; a final score ≥6 indicates high HLA-E expression, and a final score <6 indicates low to negative HLA-E expression. For nine, six, eighteen, and one cases the tumour size, depth of infiltration, LVSI (lymph-vascular space invasion), and tumour positivity of resection margins, respectively, could not be identified. P values were calculated using the Pearson Chi-Square test. P values in bold type were considered statistically significant (P < 0.05). SCC, cervical squamous cell carcinoma; ASC, cervical adenosquamous carcinoma; AC, cervical adenocarcinoma; FIGO, International Federation of Gynaecology and Obstetrics; HPV, human papillomavirus.